


PHARMACEUTICAL 2023











PHARMACEUTICAL 2023



MARIZYME INC. Rank 326 of 446

The relative strengths and weaknesses of MARIZYME INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MARIZYME INC. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 424% points. The greatest weakness of MARIZYME INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is -27%, being 70% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	1,955
Cost of Goods Sold	54
Intangible Assets	34,866
Liabilities, Current	2,922
Liabilities, Non-Current	18,344
Other Assets	1,854
Other Compr. Net Income	0
Other Expenses	33,524
Other Liabilities	0
Other Net Income	-842
Other Revenues	233
Property and Equipment	13
Research and Development	3,979
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	38,688
Liabilities	21,266
Expenses	37,557
Revenues	233
Stockholders Equity	17,422
Net Income	-38,166
Comprehensive Net Income	-38,166
Economic Capital Ratio	-27%

